Trident Pharmaceuticals' Unattributed Round

Trident Pharmaceuticals raised a round of funding on May 21, 2014.

Trident Pharmaceuticals is developing next-generation, orally active biopharmaceutical products that modulate autoreactive T cells to selectively downregulate the inflammation associated with autoimmu…

Articles about Trident Pharmaceuticals' Unattributed Round: